Search

Your search keyword '"Jagodzinski LL"' showing total 80 results

Search Constraints

Start Over You searched for: Author "Jagodzinski LL" Remove constraint Author: "Jagodzinski LL"
80 results on '"Jagodzinski LL"'

Search Results

2. Neurological Response to cART vs. cART plus integrase inhibitor and ccr5 antagonist initiated during acute HIV

3. The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon

4. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

5. An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens.

6. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.

7. Analytical validation of quantitative SARS-CoV-2 subgenomic and viral load laboratory developed tests conducted on the Panther Fusion® (Hologic) with preliminary application to clinical samples.

8. HIV-1 infected humanized DRAGA mice develop HIV-specific antibodies despite lack of canonical germinal centers in secondary lymphoid tissues.

9. Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019.

10. Validation of SARS-CoV-2 pooled testing for surveillance using the Panther Fusion® system: Impact of pool size, automation, and assay chemistry.

11. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model.

12. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.

13. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

14. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.

15. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.

16. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.

17. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.

18. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.

19. Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategies.

20. Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA.

21. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.

22. Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

23. Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection.

24. Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.

25. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.

26. Stability of Human Immunodeficiency Virus Serological Markers in Samples Collected as HemaSpot and Whatman 903 Dried Blood Spots.

27. Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.

28. Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation.

29. Characteristics of HIV-infected U.S. Army soldiers linked in molecular transmission clusters, 2001-2012.

30. Identification of Acute HIV-1 Infection by Hologic Aptima HIV-1 RNA Qualitative Assay.

31. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

32. Evaluation of Hologic Aptima HIV-1 Quant Dx Assay on the Panther System on HIV Subtypes.

33. Neurologic signs and symptoms frequently manifest in acute HIV infection.

34. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.

35. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

36. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.

37. HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.

38. Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV.

39. Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria.

40. Centralized HIV Program Oversight: An Investigation of a Case Series of New HIV Infections among US Army Soldiers, 2012 to 2013.

41. HIV outcomes in Hepatitis B virus coinfected individuals on HAART.

42. Discrepant amplification results during the development of an assay leads to reclassification of two AIDS reagent repository HIV-2 isolates as HIV-1.

43. Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients.

44. Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010.

45. Molecular epidemiology of early and acute HIV type 1 infections in the United States Navy and Marine Corps, 2005-2010.

46. Cross-sectional assessment of prevalence and correlates of blood-borne and sexually-transmitted infections among Afghan National Army recruits.

47. Efficient quantification of HIV-1 in heparin plasma spiked with cultured HIV-1 by the Roche Cobas TaqMan and Abbott RealTime HIV-1 tests.

48. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

49. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

50. Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom.

Catalog

Books, media, physical & digital resources